Skip to main content
. 2012 Mar;165(6):1992–1999. doi: 10.1111/j.1476-5381.2011.01696.x

Figure 4.

Figure 4

Increased MAP responsiveness to SNP following NOS inhibition with L-NAME (100 mg·kg−1, i.p.) is attenuated after pre-treatment with (A) the dual ETA/B receptor antagonist PD145065 (10 mg kg−1 min−1 i.v.) or (B) the ETA receptor antagonist ABT627 (200 µg·kg−1·min−1 i.v. for 10 min, followed by 100 µg·kg−1·min−1 i.v. thereafter). (C) BP responsiveness to SNP is also attenuated by PD145065 (10 mg·kg−1·min−1 i.v.) in NOS-intact rats. Data are shown as MAP changes from steady state baseline levels after infusion of saline, L-NAME, or combination of L-NAME and ET receptor antagonist. *P < 0.05 compared with controls at the same dose of vasodilator. LN, L-NAME.